Serone Capital Management / Serone Key Opportunities Fund: Hedge Fund Diligence (First Pass)

Prepared 2026-10-20 from the 71 files in sources/. The newest evidence is the Q3 2025 newsletter and the quarterly exposure history to 30 Sep 2025, so the performance and positioning data are about 12 months old. The DDQ is dated 31 Dec 2023 (about 34 months old). No Q4 2025 or 2026 performance, AUM or team data was available. This is a first-pass note, not full investment diligence, not ODD, and not a recommendation.

Source key: [DDQ23] AIMA DDQ as of 31 Dec 2023 · [OM25] Offshore Offering Memorandum, Mar 2025 · [AIFMD25] Article 23/SFDR/SFTR Supplement, Mar 2025 · [Arts25] Amended Articles (ROC filing, 19 Mar 2025) · [MF21]–[MF24] Serone Master Fund Ltd audited FS 2021–2024 · [KOF21]–[KOF24] Serone Key Opportunities Fund Ltd (offshore feeder) audited FS 2021–2024 · [QH25] Quarterly history (exposure, gross attribution) 1Q12–3Q25 · [Q3-25], [Q2-25], [Q1-25], [Q4-24], [Q3-24], [Q2-24] quarterly newsletters · [Mmm-yy] monthly newsletters Jan 2020–Mar 2024 (e.g. [Mar-20]) · [Sub] subscription documents (US tax-exempt and non-US)

---

1. First Impression

What it is. A London-based, European-focused structured credit fund. It is a Cayman master-feeder that launched in February 2012 and invests mainly in European CLO mezzanine and CLO equity, with small ABS/RMBS/CMBS sleeves [DDQ23 Strategy §1.1; Q3-25 p.4]. At 30 Sep 2025 the fund had $843m in AUM, the structured credit strategy $1.4b, and the firm $3.4b across structured, performing and special situations credit [Q3-25 p.1]. The target return is 12% p.a. over the long term [DDQ23 Strategy §1.1]. The book combines "core" mezzanine (pull-to-par, 5–10% IRRs) with "upside" CLO equity and warehouse positions, and adds tail and credit hedges at times [DDQ23 Strategy §1.1; QH25].

Why it's worth a meeting. The record is long (13.5 years), administrator-sourced, and broadly consistent across six years of letters. My spot-check found no restated monthly figures between the 2020 and 2025 composite tables. The composite compounded at about 14.9% a year from March 2012 to September 2025 net of 1.5–2% / 20% fees (my calculation from [Q3-25] p.3), with one negative calendar year (2022, -11.1%). Both large drawdowns were market-wide CLO repricings: COVID in 2020 and the loan sell-off in 2022. NAV regained its prior peak 12 and 20 months after each peak, and the manager says it was never a forced seller [Dec-20]. Service providers are institutional (Apex, European Depositary Bank, Grant Thornton, Sidley, Maples), and two of the three fund directors are independent professionals [MF24 p.1; OM25 Directors].

What is unclear, and the biggest gaps:

• Stale data at a turning point. The Q3 2025 letter says mark-to-market dispersion "accelerated since the period covered", with wider bid-ask on riskier tranches [Q3-25 p.3]. Nothing in sources/ shows what happened next. Q4 2025 through September 2026 performance is the first thing to get.
• Leverage disclosures conflict. The DDQ says "we do not use leverage" [DDQ23 Strategy §4.4–4.5]. The same DDQ gives a gross leverage range of 100–130%, a peak of 174% (Sep 2019) and repo financing [DDQ23 Strategy §6; OEF §5]. Repo stood at €185m against €730m of master NAV at end-2024, all of it with Citigroup [MF24 SoFP, note 15]. The OM legal cap is 300% gross [OM25 Summary].
• Hedges have not protected in drawdowns. On the manager's own gross attribution, hedges added +3.7% in 1Q20 against a -35.5% quarter and lost about -3.6% across 2022 [QH25 p.4].
• Valuation classification. Every CLO position, CLO equity included (about 70% of NAV), is reported as Level 2 with no Level 3 assets in any year 2020–2024 [MF21–MF24 note 14].
• Firm growth and key-person load. Firm AUM went from about $510m (Mar 2020) to $3.4b (Sep 2025), mainly in non-flagship strategies [Mar-20; Q3-25]. Investment authority still sits with the CIO (Serj Walia) and CEO (Neil Servis) [DDQ23 OEF §4.13].
• Alignment is visible but small and falling. The manager's Cayman vehicle held €4.0m in the offshore feeder at end-2024, down from €7.8m at end-2021, even though 2023–24 returns were strong [KOF22, KOF24 note 16].

---

2. Team

Facts. Ownership: Serone Capital Management LLP is 85% owned by Serone Capital Management UK Ltd (Servis majority) and 15% by other shareholders. The Cayman procurement agent, which receives the fees, is owned 42% by Servis, 25% by CANEPA SCM Holdings and 33% by other shareholders [DDQ23 Gov §1.2]. Servis, King and Walia are the control persons [DDQ23 Gov §1.3]. Headcount, turnover tables and biographies were all "available on request" [DDQ23 Gov §2.1–2.3, Table 2.3]. The OM says principal bios are "set out below", but none appear in the reviewed copy [OM25 Investment Manager]. Firm-level key-person and critical illness insurance is in place [DDQ23 Ops Table 20.1].

Read. The edge appears to be tied to Walia and Servis. They set top-down allocation, own the dealer and CLO-manager relationships the letters credit for sourcing, and the IC table lists only Walia, even though the DDQ says "at least two members" must agree to each trade [DDQ23 Gov Table 4.1 notes; OEF §4.13–4.14]. The pre-2012 careers of both principals are not documented in sources/. The 2024 corporate-credit hires broaden the firm, but they do not show depth on the CLO book itself. Investors get no key-person redemption right [DDQ23 OEF §13.1.6].

---

3. Terms, Liquidity and Alignment

Alignment facts. Serone Capital Management (Cayman) Ltd held €7.8m (2021), €7.5m (2022), €4.4m (2023) and €4.0m (2024) in the offshore feeder [KOF22–KOF24 Directors' report]. The fund returned +22.8% in 2023 and +20.7% in 2024, so this implies net withdrawals of roughly €6m over 2023–24 (my estimate; class returns differ). End-2024 holdings are about 0.5% of master NAV. The DDQ describes deferred compensation invested in the fund annually in Q1 with 3-year vesting [DDQ23 OEF §17.4, Ops §4.3.3], which may explain part of the movement. There is no compensation clawback [DDQ23 Ops §4.3.4]. Employee and management shares may carry reduced or no fees, and directors may waive or rebate fees for any shareholder [OM25 Summary; DDQ23 Ops §4.1.6]. Holdings in the Delaware LP feeder and partners' personal holdings are not disclosed.

Read. The gate and notice period fit a semi-liquid OTC book. The fee terms are generous to the manager for a strategy whose return is largely carry. The forward cash-flow yield is about 20% [Q3-25 p.3], 2024 master income was €167m against a €5m net fair-value gain [MF24 SoCI], and there is no hurdle, so a 20% fee applies to income the asset class delivers almost by construction. Offshore-feeder performance fees were €18.9m in 2024 and €8.7m in 2023 [KOF24 note 12]. Firm investor concentration is high: the top 3 investors held 58.5% and the top 10 held 87.3% of firm AUM at Dec 2023 [DDQ23 Overview §1.7]. Fund-level concentration was not provided.

---

4. Performance and Drawdowns

Composite (administrator data, net). EUR B (2/20) Mar 2012–Dec 2013, then USD A Jan 2014–Dec 2015, then USD D from Jan 2016 [Q3-25 p.3]. HFI Credit EUR figures are as charted by the manager [May-22 p.3].

*Mar–Dec 2012.

My calculations from the monthly series (not manager-reported): ITD CAGR 14.9% with 13.6% annualised volatility; ex-2012 CAGR 11.7%; Jan 2016–Sep 2025 (USD D only) 10.7%; Jan 2020–Sep 2025 8.8% with 19.3% volatility. 83% of months were positive.

Interpretation.

• Drawdowns are explainable but not small. Both large ones were market-wide technical repricings, and both recovered as the manager expected. The 2020 hole followed a peak net credit exposure of 174% at 3Q19 [QH25 p.2; DDQ23 OEF §5.2.3]. The 1Q20 loss came mostly from the "core" mezzanine book (-23.9% MTM) rather than equity (-17.6% unrealised) [QH25 p.4]. The 2022 loss came mostly from CLO equity (-12.6% unrealised in 2Q22).
• "Only one down year" is accurate by calendar year [Q3-25 p.1], but it hides the 40% intra-year drawdown in 2020.
• Repeatability. The fund beat HFI Credit EUR in 9 of 10 years from 2012 to 2021. That index is broad credit, not a CLO beta, so the comparison does not separate skill from asset-class exposure. Strong 2023–24 returns coincided with high floating-rate coupons and spread tightening, and 2024 return was almost entirely income [MF24 SoCI]. No CLO-equity or CLO-mezzanine index comparison is in sources/.
• Restatement and presentation flag. Monthly figures are consistent across the 2020–2025 letters (my cross-check). The USD ITD headline was redefined, however. In 2020 it ran from USD class inception on 1 Sep 2013 (+5.22% p.a. at Mar 2020) [Mar-20 p.1]. By Q2 2024 it was spliced back to the EUR B shares from Feb 2012 [Q2-24 footnote; Q3-25 p.1], which pulls the +61.8%/+26.0% 2012–13 years into a USD figure. The DDQ says the fund is not GIPS compliant; the track record was audited by Grant Thornton in 2023 [DDQ23 Strategy §10.2, §10.5]. The DDQ's drawdown, largest-quarter and AUM tables were all "available on request" [DDQ23 Strategy §11, OEF §16].

---

5. Strategy and Edge

Claim. The edge, per the manager, is a "rare" combination of fundamental, mark-to-market and event-driven investing in European CLOs. It rests on forensic analysis of credit, structure, legal terms and CLO managers, on origination access to deals "unavailable or not widely available", and on the principals' network [DDQ23 Strategy §1.1]. Recent letters stress controlling or majority CLO-equity stakes that let the fund drive resets, warehouse participation, and a preference for European over US CLOs because of excess spread and more creditor-friendly restructurings [Q3-25 pp.2–3; Q4-24; Q3-24].

Evidence in sources.

• Manager-reported deal outcomes include warehouse IRRs of 33% [Q3-24], "north of 20% and 40%" [Q4-24], a UK Pubs WBS trade at 22.6% IRR from Nov 2020 [Q3-25 p.2], a reset where the fund held majority equity, and a new controlling equity stake with about a 50% cash-flow yield [Q3-25 p.2]. All are unaudited and selected by the manager.
• Gross attribution shows CLO equity income of roughly 2.3–6.7% per quarter since 2023, plus mezzanine income [QH25 p.4], consistent with a carry-driven book.
• Process shift. Annual turnover fell from 111–155% (2013–2018) to 99% (2019), 81% (2020), 62% (2021), 33% (2022) and 29% (2023) [DDQ23 OEF §4.8]. Exposure moved from "core"-heavy (2012–2015) to "upside"-heavy (CLO equity 70–90% of NAV in 2017–2019 and about 70% at 3Q25) [QH25 p.3]. The DDQ says objectives have not changed in five years [DDQ23 Strategy §1.2]. The data show a move from active trading toward holding and structuring CLO equity.

Still to diligence. How much of the return is European CLO equity and mezzanine beta versus selection, structuring and timing. Whether the hit rate on resets, warehouses and calls holds up when loan prices are weak. Whether controlling equity stakes create concentration in specific CLO managers or vintages. The fund's own hedging record does not yet support the claim of "low correlation to the wider markets" [DDQ23 Strategy §1.1].

---

6. Portfolio, Risk and Capacity

Exposure (3Q25, % NAV) [QH25 pp.2–3]: CLO mezzanine 60.7%, CLO equity/warehousing 70.1%, other structured 5.0%, CLO senior 0.1%. Gross long about 136%; credit hedges -15.0%; net credit 120.8%; macro hedges -41.7%; net 79.2%. Look-through: CLO 96.3%, UK 18%, France 18%, Germany 13%, Netherlands 13%, US corporate risk 9.5% [Q3-25 p.4].

Leverage and financing. Repo liabilities were €154m (2020), €94m (2021), €98m (2022), €169m (2023) and €185m (2024) [MF21–MF24 SoFP]. At end-2024 the whole €185m sat with a single counterparty, Citigroup Global Markets, which is also the fund's cash bank. At end-2023 it was spread across JPM (€80m), BNP (€59m), MS (€26m) and SocGen (€4m) [MF24 note 15]. Repo is used "on higher quality assets" [DDQ23 OEF §6.7]. The DDQ lists eight repo and five ISDA counterparties, and no prime broker [DDQ23 OEF §7.1–7.2]. The March 2025 OM names Barclays as prime broker [OM25 Summary]. This needs reconciling. The fund reduced Credit Suisse exposure by unwinding reverse repo [DDQ23 Ops §10.8].

Risk limits [DDQ23 Strategy §5.1.1]: gross leverage 130% ("current internal limit"); cash flagged below 5%; stressed positions flagged when 30% of the book trades under 50; single CLO manager flagged above 30% (tier 1) or 20%; issuer flagged above 15%; price-move flags. These are flags to the CRO, not hard stops. There are no stop-losses, no VaR, no hard-coded pre-trade restrictions, and compliance checks are manual [DDQ23 Ops §2.2.4–2.3.4, Strategy §5.3, §8.4]. The DDQ reports 120–200 positions at under 0.5% to 2.5% of capital each, and about 160 at Dec 2023 [DDQ23 Strategy §8.7]. Net credit exposure ran at 152–174% throughout 2Q19–4Q19, above today's 130% gross limit, but the DDQ answers "No" to material leverage adjustments in the past five years [QH25 p.2; DDQ23 Strategy §6.10]. Gross and net measures may be defined differently.

Hedging. Hedging is discretionary tail optionality and index credit protection with "no formal limits" [DDQ23 Strategy §3.4.3–3.4.4]. Gross hedge P&L was +3.7% (1Q20), about -3.6% (2022), about -2.9% (2023), about -0.7% (2024) and about -1.5% (2025 YTD) [QH25 p.4]. Macro hedge notional rose to -41.7% at 3Q25 [QH25 p.2].

Capacity. No capacity figure is stated. Subscriptions are accepted "based, in part, on the capacity of the Fund" [OM25]. The structured strategy ($1.4b) is larger than the fund ($843m) [Q3-25 p.1]. The other vehicles and the allocation policy between them are not described.

---

7. Key Counterparties and ODD Snapshot

Disclosed facts worth noting. All instruments are valued by an "independent valuation expert" (100%) and the manager cannot override, but "Serone's investment team have the right to validate marks" [DDQ23 OEF §18.4, §18.7]. All CLO and ABS holdings are classified as Level 2 in 2020–2024, with zero Level 3 [MF21–MF24 note 14]. The DDQ reports no regulatory review to date, no proceedings, no NAV restatements, no late NAVs and no trade errors [DDQ23 Overview §2.4, §2.7; OEF §18.14–18.16; Ops §9.9]. There is no aged-items list in middle office [DDQ23 Ops §13.6]. Founder shares with voting rights are held by the procurement agent [OM25 Summary; Arts25]. The SOC 1, compliance manual, valuation policy and Form ADV were all "available on request". This snapshot is not an assessment of operational quality.

---

8. Known / Unknown / Ask Next

---

9. Diligence Questions

Incentive Alignment

• What is total partner and employee capital across both feeders, and why did the Cayman vehicle's holding fall by about half in 2023–24?
• Who is CANEPA SCM Holdings, what economics does its 25% of the fee-receiving entity carry, and does it have governance rights?
• Why no hurdle, given that roughly 20% cash yield is the base of the return?

Edge & Repeatability

• How much of 2023–24 came from European CLO beta and higher base rates, and how much from selection or structuring? Show attribution against a CLO-equity benchmark.
• Turnover fell from over 100% to about 30%. Is the trading edge described in 2013–2019 still central, or has the strategy become a CLO-equity hold-and-reset book?
• How often do warehouses and resets underperform, and what were the worst outcomes?

Performance & Drawdowns

• What happened to NAV and marks from October 2025 onward, given the dispersion flagged in the Q3 2025 letter?
• In March 2020, what margin calls were met, how much repo was cut, and what assets were sold?
• Why did hedges lose money across 2022, and what is the hedge budget today with macro hedges at -42%?
• Why was the USD ITD figure re-based to 2012?

Team Stability

• Who besides Walia can run the CLO book? What would happen if he left?
• How is investment-team time split across three strategies after firm AUM grew from about $0.5b to $3.4b?
• Why does the IC list only the CIO when the policy requires two approvers?

Risk, Financing & Capacity

• How do the 130% gross limit, the 152–174% net exposure in 2019 and the 300% OM cap reconcile? When was the 130% limit adopted?
• What are the repo haircuts, tenors and margin triggers? Why was all repo with Citigroup at end-2024 after four banks at end-2023, and is that still the case? Is Barclays now prime broker?
• Why is CLO equity Level 2? What share of marks are dealer quotes, vendor prices or models?
• What is realistic capacity for this fund and the structured strategy?

---

10. Reference Check Prep

Current investors. Was communication timely and candid in March 2020 and mid-2022? Were gates, holdbacks or in-specie terms ever discussed or threatened? Any surprises on fees or marks?

Former investors. Did you redeem after 2020 or 2022, and was the investor-level gate applied? Why did you leave: performance, transparency, team, or fees?

Former employees. Does the process depend on Walia and Servis? Do the CRO's flags lead to position cuts in practice? How are valuation disputes with the administrator handled? What has turnover been on the CLO team?

Service providers (Apex, EDB, Grant Thornton). What share of CLO-equity marks are independently sourced versus manager-validated? Were there pricing challenges in Q4 2025? Were there recurring reconciliation breaks?

---

11. Suggested Materials Request List

1. Monthly NAV, AUM and net flows by class from inception to date, including Q4 2025 and 2026 letters
2. Current DDQ (2025 or 2026), with the tables deferred in the Dec 2023 version: drawdowns, largest quarters, AUM history, headcount, investor types, Level 1/2/3 split
3. Current portfolio snapshot: top 20 positions, CLO-manager and vintage concentration, cash-flow yield by position bucket
4. Valuation policy, pricing-source breakdown, administrator transparency report, and Level 2 rationale for CLO equity
5. Repo and ISDA terms (haircuts, tenors, triggers) and prime brokerage agreement status
6. Risk reports and stress tests; hedge-book history and budget
7. Full realised outcomes for warehouses, resets and controlling-equity trades since 2018
8. Form ADV Part 2A/2B; organisational chart; bios for Servis and Walia; leavers since 2020
9. Total GP and employee investment across both feeders; Cayman entity ownership and CANEPA terms
10. SOC 1 (Apex); compliance consultant identity; latest annual compliance review summary
11. Grant Thornton performance-verification letter (2023); 2025 audited FS for master and feeders
12. Neil Servis annual CEO letters (referenced in [Dec-23], not in sources/)
13. Reference list: current and former investors, former employees

---

12. Sources Reviewed

• DDQ – AIMA Illustrative Questionnaire, Serone Capital Management LLP, as of 31 Dec 2023 (161 pp.)
• Offering documents – Confidential Offering Memorandum, Serone Key Opportunities Fund Ltd, Mar 2025; AIFMD Art. 23 / SFDR / SFTR Supplement, Mar 2025; Amended Memorandum and Articles (ROC filing, resolution dated 19 Mar 2025); Subscription Documents (US Tax-Exempt; non-US)
• Audited financials – Serone Master Fund Ltd FY2021, FY2022, FY2023, FY2024 (Grant Thornton Cayman; signed 11 Apr 2022, 14 Apr 2023, 18 Apr 2024, 25 Apr 2025); Serone Key Opportunities Fund Ltd FY2021–FY2024
• Quarterly history – Fund book / region / seniority exposures and gross P&L attribution, 1Q12–3Q25 ("Quarterly His 2025Q3")
• Newsletters – Monthly, Jan 2020–Mar 2024 (some file names are truncated: "September 202/203/204/205" are Sep 2023/2022/2021/2020); Quarterly Q2 2024–Q3 2025. No Q4 2025 or 2026 material.
• Outside sources/ – none used. The Ambrus note in this folder tree was used only as a format reference.